

65. (New) The primer of claim 21, wherein said nucleotide sequence consists of SEQ. ID. NO.
2058.

66. (New) The primer of claim 21, wherein said nucleotide sequence consists of SEQ. ID. NO.
2965.

67. (New) The primer of claim 21, wherein said nucleotide sequence consists of SEQ. ID. NO.
3084.

68. (New) The primer of claim 21, wherein said nucleotide sequence consists of SEQ. ID. NO.
4937.

REMARKS

In the Office Action dated February 2, 1999, the Examiner had indicated that claims 1, 3, 13, and 21 were allowed and that claims 2, 4-12, 14-20, and 22-28 were rejected. All of the rejected claims were canceled above without prejudice to future prosecution in order to facilitate the prompt issuance of a patent on the subject matter presently indicated as allowable. Those cancellations do not constitute an admission that any of the canceled subject matter is unpatentable and Applicant reserves the right to prosecute corresponding claims in future applications.

New claims were entered above which each depend from one of the allowed claims and which each specify only one of the SEQ. ID. NOS. listed in a Markush group in the corresponding independent claim. Thus, the new claims add no new matter. As each of the new dependent claims contains a subset


of the subject matter of the allowed independent claims, Applicant submits that the newly submitted claims are also all allowable.

All of the pending claims are in condition for allowance and Applicant respectfully requests a notice to that effect.

No fee is believed due in connection with this communication. However, if any fee is due, kindly charge the appropriate amount to Deposit Account No. 12-2475.

Respectfully submitted,

LYON & LYON LLP

By 
Wesley B. Ames
Reg. No. 40,893

First Interstate World Center
633 West Fifth Street, 47th Floor
Los Angeles, CA 90071-2066
Telephone: (619) 552-8400